Comparison of fecal and blood metabolome reveals inconsistent associations of the gut microbiota with cardiometabolic diseases

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: Feb. 2, 2023

Abstract Blood metabolome is commonly used in human studies to explore the associations of gut microbiota-derived metabolites with cardiometabolic diseases. Here, a cohort 1007 middle-aged and elderly adults matched fecal metagenomic (149 species 214 pathways) paired blood targeted metabolomics data (132 metabolites), we find disparate taxonomic composition microbial pathways when using or metabolites. For example, observe that fecal, but not butyric acid significantly associates both microbiota prevalent type 2 diabetes. These findings are replicated an independent validation involving 103 adults. Our results suggest caution should be taken inferring microbiome-cardiometabolic disease from either data.

Language: Английский

---

The Implication of the Gut Microbiome in Heart Failure

Cells, Journal Year: 2023, Volume and Issue: 12(8), P. 1158 - 1158

Published: April 14, 2023

Heart failure is a worldwide health problem with important consequences for the overall wellbeing of affected individuals as well healthcare system. Over recent decades, numerous pieces evidence have demonstrated that associated gut microbiota represent an component human physiology and metabolic homeostasis, can affect one’s state or disease directly, through their derived metabolites. The advances in microbiome studies shed light on relationship between cardiovascular system, revealing its contribution to development heart failure-associated dysbiosis. HF has been linked dysbiosis, low bacterial diversity, intestinal overgrowth potentially pathogenic bacteria decrease short chain fatty acids-producing bacteria. An increased permeability allowing microbial translocation passage bacterial-derived metabolites into bloodstream progression. A more insightful understanding interactions microbiome, risk factors mandatory optimizing therapeutic strategies based modulation offering individualized treatment. purpose this review summarize available data regarding influence communities HF, order obtain better multi-layered complex relationship.

Language: Английский

---

The Implication of Short-Chain Fatty Acids in Obesity and Diabetes

Microbiology Insights, Journal Year: 2023, Volume and Issue: 16

Published: Jan. 1, 2023

Evidence indicates that short-chain fatty acids (SCFAs) generated from the gut microbiota play crucial roles in host metabolism. They contribute to metabolic regulation and energy acquisition of by influencing development disorders. This review aims synthesize recent advances literature investigate implication SCFAs modulation obesity diabetes pathologies. For a better understanding relationships between metabolism, we need answer some questions: What is biochemistry SCFAs, how they are microbiota? bacteria producing which routes? How absorbed transported different mechanisms receptors? involved pathologies?

Language: Английский

---

Linking human milk oligosaccharide metabolism and early life gut microbiota: bifidobacteria and beyond

Microbiology and Molecular Biology Reviews, Journal Year: 2024, Volume and Issue: 88(1)

Published: Jan. 11, 2024

SUMMARY Human milk oligosaccharides (HMOs) are complex, multi-functional glycans present in human breast milk. They represent an intricate mix of heterogeneous structures which reach the infant intestine intact form as they resist gastrointestinal digestion. Therefore, confer a multitude benefits, directly and/or indirectly, to developing neonate. Certain bifidobacterial species, being among earliest gut colonizers breast-fed infants, have adapted functional capacity metabolize various HMO structures. This ability is typically observed infant-associated bifidobacteria, opposed bifidobacteria associated with mature microbiota. In recent years, information has been gleaned regarding how these well certain other taxa able assimilate HMOs, including mechanistic strategies enabling their acquisition and consumption. Additionally, complex metabolic interactions occur between microbes facilitated by utilization breakdown products released from degradation. Interest HMO-mediated changes microbial composition function focal point numerous studies, times fueled availability individual biosynthetic some now commonly included formula. this review, we outline main assimilatory catabolic employed discuss that exhibit glycan degradation capacity, cover HMO-supported cross-feeding related metabolites described thus far.

Language: Английский

---

Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease

BMC Gastroenterology, Journal Year: 2024, Volume and Issue: 24(1)

Published: Jan. 23, 2024

Abstract Background Alterations in the production of short-chain fatty acids (SCFAs) may reflect disturbances gut microbiota and have been linked to metabolic dysfunction-associated steatotic liver disease (MASLD). We assessed plasma SCFAs patients with MASLD healthy controls. Methods Fasting venous blood samples were collected eight measured using gas chromatography-tandem mass spectrometry (GC-MS/MS). Relative between-group differences circulating SCFA concentrations estimated by linear regression, relation between concentrations, MASLD, fibrosis severity was investigated logistic regression. Results The study includes 100 (51% mild/no 49% significant fibrosis) 50 Compared controls, had higher propionate (21.8%, 95% CI 3.33 43.6, p = 0.02), formate (21.9%, 6.99 38.9, 0.003), valerate (35.7%, 4.53 76.2, α-methylbutyrate (16.2%, 3.66 30.3, 0.01) but lower acetate (− 30.0%, − 40.4 17.9, < 0.001). Among positively associated ( butyrate 0.03), 0.02). Six significantly increased F4 fibrosis. Conclusions In present study, severity, further research is needed elucidate potential mechanisms underlying our observations assess possible benefit therapies modulating microbiota.

Language: Английский

---